Patient-specific stem cells and cardiovascular drug discovery

doi:10.1001/jama.2013.282409

. 2013 Nov 20;310(19):2039-40.

doi: 10.1001/jama.2013.282409.

Patient-specific stem cells and cardiovascular drug discovery

Nicholas M Mordwinkin¹, Andrew S Lee, Joseph C Wu

Affiliations

Affiliation

¹ Stanford Cardiovascular Institute2Department of Medicine, Division of Cardiology3Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California.

PMID: 24240927
PMCID: PMC4033311
DOI: 10.1001/jama.2013.282409

Free PMC article

Patient-specific stem cells and cardiovascular drug discovery

Nicholas M Mordwinkin et al. JAMA. 2013.

Free PMC article

. 2013 Nov 20;310(19):2039-40.

doi: 10.1001/jama.2013.282409.

Authors

Nicholas M Mordwinkin¹, Andrew S Lee, Joseph C Wu

Affiliation

¹ Stanford Cardiovascular Institute2Department of Medicine, Division of Cardiology3Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California.

PMID: 24240927
PMCID: PMC4033311
DOI: 10.1001/jama.2013.282409

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Patient-specific iPSC-CMs make an ideal platform for phenotypic drug discovery assays because of their capacity to recapitulate cardiac phenotypes. Coupled with current advances in high-throughput screening technologies, patient-specific iPSC-CMs will accelerate our ability to investigate the molecular mechanisms of cardiovascular disorders that are resistant to current pharmaceutical treatments and to identify novel therapeutic targets for these diseases.

See this image and copyright information in PMC

Comment in

Stem cells and cardiovascular drug development.
Rao RC, Dlouhy BJ. Rao RC, et al. JAMA. 2014 Mar 12;311(10):1070. doi: 10.1001/jama.2014.631. JAMA. 2014. PMID: 24618975 No abstract available.
Stem cells and cardiovascular drug development--reply.
Mordwinkin NM, Lee AS, Wu JC. Mordwinkin NM, et al. JAMA. 2014 Mar 12;311(10):1070-1. doi: 10.1001/jama.2014.634. JAMA. 2014. PMID: 24618976 No abstract available.

Cited by

Challenges and innovation: Disease modeling using human-induced pluripotent stem cell-derived cardiomyocytes.
Reilly L, Munawar S, Zhang J, Crone WC, Eckhardt LL. Reilly L, et al. Front Cardiovasc Med. 2022 Aug 12;9:966094. doi: 10.3389/fcvm.2022.966094. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36035948 Free PMC article. Review.
Electrophysiology of hiPSC-Cardiomyocytes Co-Cultured with HEK Cells Expressing the Inward Rectifier Channel.
Costa ADS, Mortensen P, Hortigon-Vinagre MP, van der Heyden MAG, Burton FL, Gao H, Simitev RD, Smith GL. Costa ADS, et al. Int J Mol Sci. 2021 Jun 21;22(12):6621. doi: 10.3390/ijms22126621. Int J Mol Sci. 2021. PMID: 34205607 Free PMC article.
Race and Genetics in Congenital Heart Disease: Application of iPSCs, Omics, and Machine Learning Technologies.
Mullen M, Zhang A, Lui GK, Romfh AW, Rhee JW, Wu JC. Mullen M, et al. Front Cardiovasc Med. 2021 Feb 17;8:635280. doi: 10.3389/fcvm.2021.635280. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33681306 Free PMC article. Review.
3D Bioprinting: The Roller Coaster Ride to Commercialization.
Elemoso A, Shalunov G, Balakhovsky YM, Ostrovskiy AY, Khesuani YD. Elemoso A, et al. Int J Bioprint. 2020 Jul 30;6(3):301. doi: 10.18063/ijb.v6i3.301. eCollection 2020. Int J Bioprint. 2020. PMID: 33088989 Free PMC article. Review.
Developments with 3D bioprinting for novel drug discovery.
Satpathy A, Datta P, Wu Y, Ayan B, Bayram E, Ozbolat IT. Satpathy A, et al. Expert Opin Drug Discov. 2018 Dec;13(12):1115-1129. doi: 10.1080/17460441.2018.1542427. Epub 2018 Nov 1. Expert Opin Drug Discov. 2018. PMID: 30384781 Free PMC article. Review.

See all "Cited by" articles

References

1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews. Drug Discovery. 2012 Mar;11(3):191–200. - PubMed
1. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews. Drug Discovery. 2010 Mar;9(3):203–214. - PubMed
1. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012 Jan 6;10(1):16–28. - PMC - PubMed
1. Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacology & Therapeutics. 2013 Jun;138(3):470–484. - PubMed
1. Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013 Apr 23;127(16):1677–1691. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews. Drug Discovery. 2012 Mar;11(3):191–200. - PubMed

[2] Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews. Drug Discovery. 2012 Mar;11(3):191–200. - PubMed

[3] Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews. Drug Discovery. 2010 Mar;9(3):203–214. - PubMed

[4] Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews. Drug Discovery. 2010 Mar;9(3):203–214. - PubMed

[5] Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012 Jan 6;10(1):16–28. - PMC - PubMed

[6] Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012 Jan 6;10(1):16–28. - PMC - PubMed

[7] Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacology & Therapeutics. 2013 Jun;138(3):470–484. - PubMed

[8] Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacology & Therapeutics. 2013 Jun;138(3):470–484. - PubMed

[9] Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013 Apr 23;127(16):1677–1691. - PMC - PubMed

[10] Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013 Apr 23;127(16):1677–1691. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Patient-specific stem cells and cardiovascular drug discovery

Affiliation

Patient-specific stem cells and cardiovascular drug discovery

Authors

Affiliation

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources